Therapeutic Potential of Monteplase in Acute Myocardial Infarction

Authors: Inoue, Teruo¹; Nishiki, Ryoichi²; Kageyama, Manabu³; Node, Koichi¹

Source: American Journal of Cardiovascular Drugs, Volume 5, Number 4, 2005 , pp. 225-231(7)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Thrombolysis with conventional thrombolytic agents prior to percutaneous coronary intervention (PCI) has had no impact on the treatment of acute myocardial infarction (AMI). However, the development of mutant tissue type plasminogen activators (mt-PA) has prompted us to reassess the combination of thrombolysis and PCI. Monteplase is a newly developed mt-PA that can be administered as a single intravenous bolus injection. The results of the COMA (COmbining Monteplase with Angioplasty) trial, suggest that monteplase administration prior to emergent PCI in AMI improves 6-month outcomes and possibly the long-term prognosis of myocardial infarction. Combining monteplase administration on presentation at a community hospital with prompt transfer to a tertiary center for PCI would be an ideal strategy for the treatment of AMI.

Keywords: Myocardial infarction; Monteplase; Plasminogen activators; Thrombolytics

Document Type: Leading article

Affiliations: 1: 1 Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine, Saga, Japan 2: 2 Pharmaceuticals Department, Eisai Co. Ltd, Tokyo, Japan 3: 3 Product Planning Division, Eisai Co. Ltd, Tokyo, Japan

Publication date: 2005-01-01